Company Overview and News

KLCI pares gains as regional sentiment turns tepid

6h theedgemarkets
KUALA LUMPUR (June 20): The FBM KLCI pared its gains substantially at the midday break today, tracking its regional peers as China's stock markets fell.
HLFBF APEXF PBLOF 7090 UPBMF 1082 5681 BATS 4162 1295 2089 7077 5014 9598 KLKBY 2445 3301 2216 5819 MYPRY

KLCI snaps losing streak, tracks rebound at regional markets

9h theedgemarkets
KUALA LUMPUR (June 20): The FBM KLCI snapped its losing streak and rose in early trade this morning, tracking the rebound at most regional markets.

KLCI extends loss, drops 0.65% as banks drag

2018-06-19 theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI extended its loss at the midday break today and dropped 0.65%, dragged by banking heavyweights Public Bank Bhd and Malayan Banking Bhd (Maybank).
HLFBF APEXF PBLOF 7090 MLYNF 7113 4065 TPGVF 1295 2852 3026 3301 2836 MLYBY 1082 5681 0096 5202 7123 TGLVY 1155 4588 1996 0026 3719

KLCI down 0.42% in line with the regional pullback

2018-06-19 theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI was down 0.42% at mid-morning today, in line with the pullback at most regional markets as the tariff tit-for-tat between the US and China intensified.
HLFBF APEXF 7090 5150 4065 1082 5681 BATS 4162 5014 7123 3026 3867 1996 0026 MYPRY 3719

KLCI falls 0.37% in line with loss at regional markets

2018-06-19 theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI fell 0.37% in early trade this morning in line with the retreat at most regional markets, on heightened worries over the trade spat between the world’s two largest economies.
HLFBF KLKBY 2445 PBLOF 4065 1082 5681 BATS 4162 1295 7153 3719

KLCI down 0.41%, select blue chips drag

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): The FBM KLCI fell 0.41% at mid-morning today, tracking losses at regional markets, weighed by select index-linked blue chips.
HLFBF 7293 PBLOF SPMXF 1082 7113 TPGVF BATS 4162 1295 7077 6033 TGLVY PNADF SPMXY 5226 1201 2836 BSMAF PNAGF 1818

KLCI down 0.38% as regional markets turn choppy

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI fell 0.38% at the midday break today against the backdrop of choppy regional markets, dragged by select index-linked blue chips.
HLFBF 7251 MLYBY MLYNF UPBMF 1082 7113 5032 8664 TPGVF BATS 4162 2089 9334 2852 TGLVY 1155 0047 5347 3301 TNABY TNABF GEBHF

KLCI remains under pressure as select blue chips weigh

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI remained under pressure at mid-morning today, dragged by select index-linked blue chips.
HLFBF 7251 UPBMF 1082 7113 5032 TPGVF BATS 4162 7153 5168 2089 9334 TGLVY 5139 0047 5347 3026 0104 0900 6645 TNABY TNABF HRGHY

Bursa Malaysia ends lower

2018-06-11 malaymail
KUALA LUMPUR, June 11 — Bursa Malaysia bucked the trend in most regional markets to end lower today, weighed by finance related stocks led by CIMB, Public Bank and Hong Leong Financial Group, dealers said.
HLFBF 7251 PBLOF 1082 7036 1295 BSMAF 1818

KLCI pares loss, poised to claw into positive zone

2018-06-11 theedgemarkets
KUALA LUMPUR (June 11): The FBM KLCI pared down some of its losses at mid-morning and looked poised to claw into positive territory later in the morning.
HLFBF MLYBY MLYNF 8621 1082 7113 TPGVF 1163 9334 2852 TGLVY 1155 3026 3301 3867 2836

KLCI pares gains, stays up 0.49% in line with region

KUALA LUMPUR: Bursa Malaysia pared some of its gains at close on Thursday but remained up 0.47%, tracking regional markets. At 5pm, the 30-stock FBM KLCI index was up 8.68 points, or 0.49% to 1,785.81. The benchmark index had earlier risen to its intra-day high of 1,801.42. The index opened 2.84 points higher at 1,779.97. Trading volume surged to 4.06 billion shares worth RM3.24bil as compared with Wednesday’s 2.
HLFBF PNADF 5347 TNABY 5819 1082 6399 TNABF BSMAF PNAGF 6033 1818

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...